Zobrazit v EDS

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes: new cardiovascular, kidney, and metabolic outcomes

Uloženo v:

Podrobná bibliografie
Název:	CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes: new cardiovascular, kidney, and metabolic outcomes
Autoři:	Schnell, Oliver, Barnard-Kelly, Katharine, Battelino, Tadej, Ceriello, Antonio, Larsson, Helena Elding, Fernández-Fernández, Beatriz, Forst, Thomas, Frias, Juan-Pablo, Gavin, James R, Giorgino, Francesco, Groop, Per-Henrik, Heerspink, Hiddo J L, Herzig, Stephan, Hummel, Michael, Huntley, George, Ibrahim, Mahmoud, Itzhak, Baruch, Jacob, Stephan, Ji, Linong, Kosiborod, Mikhail, Lalic, Nebosja, Macieira, Sofia, Malik, Rayaz A, Mankovsky, Boris, Marx, Nikolaus, Mathieu, Chantal, Müller, Timo D, Ray, Kausik, Rodbard, Helena W, Rossing, Peter, Rydén, Lars, Schumm-Draeger, Petra-Maria, Schwarz, Peter, Škrha, Jan, Snoek, Frank, Tacke, Frank, Taylor, Bruce, Jeppesen, Britta Tendal, Tesfaye, Solomon, Topsever, Pinar, Vilsbøll, Tina, Yu, Xuefeng, Standl, Eberhard
Přispěvatelé:	HUS Abdominal Center, Research Programs Unit, Department of Medicine, Per Henrik Groop / Principal Investigator, Clinicum, Nefrologian yksikkö, Schnell, Oliver, Barnard-Kelly, Katharine, Battelino, Tadej, Ceriello, Antonio, Larsson, Helena Elding, Fernández-Fernández, Beatriz, Forst, Thoma, Frias, Juan-Pablo, Gavin, James R, Giorgino, Francesco, Groop, Per-Henrik, Heerspink, Hiddo J L, Herzig, Stephan, Hummel, Michael, Huntley, George, Ibrahim, Mahmoud, Itzhak, Baruch, Jacob, Stephan, Ji, Linong, Kosiborod, Mikhail, Lalic, Nebosja, Macieira, Sofia, Malik, Rayaz A, Mankovsky, Bori, Marx, Nikolau, Mathieu, Chantal, Müller, Timo D, Ray, Kausik, Rodbard, Helena W, Rossing, Peter, Rydén, Lar, Schumm-Draeger, Petra-Maria, Schwarz, Peter, Škrha, Jan, Snoek, Frank, Tacke, Frank, Taylor, Bruce, Jeppesen, Britta Tendal, Tesfaye, Solomon, Topsever, Pinar, Vilsbøll, Tina, Yu, Xuefeng, Standl, Eberhard
Zdroj:	Cardiovasc Diabetol Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-17 (2024) Schnell, O, Barnard-Kelly, K, Battelino, T, Ceriello, A, Larsson, H E, Fernández-Fernández, B, Forst, T, Frias, J-P, Gavin, J R, Giorgino, F, Groop, P-H, Heerspink, H J L, Herzig, S, Hummel, M, Huntley, G, Ibrahim, M, Itzhak, B, Jacob, S, Ji, L, Kosiborod, M, Lalic, N, Macieira, S, Malik, R A, Mankovsky, B, Marx, N, Mathieu, C, Müller, T D, Ray, K, Rodbard, H W, Rossing, P, Rydén, L, Schumm-Draeger, P-M, Schwarz, P, Škrha, J, Snoek, F, Tacke, F, Taylor, B, Jeppesen, B T, Tesfaye, S, Topsever, P, Vilsbøll, T, Yu, X & Standl, E 2024, 'CVOT Summit Report 2023 : new cardiovascular, kidney, and metabolic outcomes', Cardiovascular Diabetology, vol. 23, no. 1, 104. https://doi.org/10.1186/s12933-024-02180-8 Schnell, O, Barnard-Kelly, K, Battelino, T, Ceriello, A, Larsson, H E, Fernández-Fernández, B, Forst, T, Frias, J P, Gavin, J R, Giorgino, F, Groop, P H, Heerspink, H J L, Herzig, S, Hummel, M, Huntley, G, Ibrahim, M, Itzhak, B, Jacob, S, Ji, L, Kosiborod, M, Lalic, N, Macieira, S, Malik, R A, Mankovsky, B, Marx, N, Mathieu, C, Müller, T D, Ray, K, Rodbard, H W, Rossing, P, Rydén, L, Schumm-Draeger, P M, Schwarz, P, Škrha, J, Snoek, F, Tacke, F, Taylor, B, Jeppesen, B T, Tesfaye, S, Topsever, P, Vilsbøll, T, Yu, X & Standl, E 2024, ' CVOT Summit Report 2023 : new cardiovascular, kidney, and metabolic outcomes ', Cardiovascular Diabetology, vol. 23, no. 1, 104 . https://doi.org/10.1186/s12933-024-02180-8 Cardiovasc Diabetol 23(1), 104 (2024). doi:10.1186/s12933-024-02180-8
Informace o vydavateli:	Springer Science and Business Media LLC, 2024.
Rok vydání:	2024
Témata:	Blood Glucose, MASLD, Heart failure, Finerenone, Guideline, Guidelines, Diabete, Kidney, Teplizumab, NAFLD, Chronic kidney disease, Diabetes Mellitus, Diseases of the circulatory (Cardiovascular) system, Humans, Obesity, GLP-1 RA, Renal Insufficiency, Chronic, Heart Failure, 2. Zero hunger, CGM, Blood Glucose Self-Monitoring, Diabetes, Comment, SGLT2 inhibitor, Stroke Volume, Cardiovascular disease, General medicine, internal medicine and other clinical medicine, 3. Good health, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic/diagnosis [MeSH], Blood Glucose Self-Monitoring [MeSH], Cardiovascular Diseases/diagnosis [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Blood Glucose [MeSH], Diabetes Mellitus/drug therapy [MeSH], Stroke Volume [MeSH], Humans [MeSH], Cardiovascular Diseases/epidemiology [MeSH], Kidney [MeSH], Cardiovascular Diseases/prevention, Heart Failure/complications [MeSH], Obesity/complications [MeSH], Renal Insufficiency, Chronic/therapy [MeSH], Renal Insufficiency, Chronic/epidemiology [MeSH], Cardiovascular Diseases, RC666-701
Popis:	The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).
Druh dokumentu:	Article Other literature type Contribution for newspaper or weekly magazine
Popis souboru:	application/pdf
Jazyk:	English
ISSN:	1475-2840
DOI:	10.1186/s12933-024-02180-8
DOI:	10.18154/rwth-conv-253571
Přístupová URL adresa:	https://pubmed.ncbi.nlm.nih.gov/38504284 https://doaj.org/article/167ffccba8024cf1934fce0e0b20bdf0 https://research.rug.nl/en/publications/280963d5-ecc9-4203-a0bf-d78648d7aacf https://hdl.handle.net/11370/280963d5-ecc9-4203-a0bf-d78648d7aacf https://doi.org/10.1186/s12933-024-02180-8 https://research.vumc.nl/en/publications/a1bb61ac-f3e1-4382-b05e-7302b74224b5 http://hdl.handle.net/10138/575858 https://curis.ku.dk/ws/files/386454640/s12933_024_02180_8.pdf https://repository.publisso.de/resource/frl:6518426 https://publications.rwth-aachen.de/record/1007217
Rights:	CC BY URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (http://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Přístupové číslo:	edsair.doi.dedup.....b23786c58b2c8c85777472110c9f00e8
Databáze:	OpenAIRE

View record at OpenAIRE

Full Text Finder

Nájsť tento článok vo Web of Science

Popis
Abstrakt:	The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).
ISSN:	14752840
DOI:	10.1186/s12933-024-02180-8